CXCL4/PF4 Protein, Human

Catalog Number: UA040566 Brand: UA BIOSCIENCE

Price:

$115 USD

Size: 10μg 50μg 100μg 500μg 1mg

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Species	Human
Synonyms	Platelet factor 4, PF-4, C-X-C motif chemokine 4, Iroplact, Oncostatin-A
Accession	P02776
Amino Acid Sequence	Glu 32-Ser101 with His Tag at the C-Terminus
Expression System	Yeast
Molecular Weight	12-13 kDa (Reducing)
Purity	>95% by SDS-PAGE and HPLC.
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	His Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	20mM Sodium Citrate, 150mM NaCl, 5% Trehalose, pH5.0
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. ·3 months, -20 to -80℃ under sterile conditions after reconstitution. ·1 week, 2 to 8℃ under sterile conditions after reconstitution. ·Please avoid repeated freeze-thaw cycles.
Reference	Nat Commun. 2023 Aug 16;14(1):4375. Cytokine Growth Factor Rev. 2011 Feb;22(1):1-18.

Background

CXCL4, also known as Platelet Factor 4 (PF4), is a member of the C-X-C chemokine family and was the first chemokine to be identified. The human PF4 gene encodes a small protein of approximately 7.8 kDa comprising 70 amino acids in its mature form. CXCL4 is predominantly localized within the alpha granules of platelets, with a remarkably high concentration of approximately 20 μg of PF4 present in every 1×10⁹ platelet cells. In plasma, PF4 is found at a concentration of approximately 2–10 ng/mL.

CXCL4 exerts pleiotropic biological functions. It is recognized as a potent antiangiogenic chemokine that inhibits endothelial cell proliferation and migration, leading to suppression of angiogenesis. The angiostatic activity of CXCL4 involves multiple mechanisms, including interference with angiogenic growth factors such as bFGF-2 and VEGF165, activation of the CXCR3B receptor (a splice variant of CXCR3), interactions with integrins, and interference with cell cycle progression.